News

ASCO 2015: Dr. Walter M. Stadler gives his top picks in genitourinary research


 

References

Dr. Walter M. Stadler picks the upcoming ASCO presentations he anticipates to be the most interesting in genitourinary research.

4501 A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

Dr. Walter M. Stadler

Dr. Walter M. Stadler

4502 Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.

4505 A phase II/III, double-blind, randomized trial comparing maintenance lapatinib with placebo after first-line chemotherapy in HER1/2 positive metastatic bladder cancer patients.

4509 Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.

4516Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

5001Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476). The Oncology Report covered this study following a pre-meeting press conference.

LBA5002A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

5000The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).

5003Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

5004Defining a molecular subclass of treatment resistant prostate cancer.

5007 TROG 03.06 and VCOG PR 01-03: The “timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative randomized phase III trial.

Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.

Recommended Reading

Circulating tumor cells and LDH level provide surrogate for survival in advanced prostate cancer
MDedge Hematology and Oncology
New drugs signal promise for rare leukemia, prostate cancer
MDedge Hematology and Oncology
Cixutumumab provided no boost to androgen deprivation therapy
MDedge Hematology and Oncology
Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting
MDedge Hematology and Oncology
AACR: Biomarker of response to olaparib found
MDedge Hematology and Oncology
Androgen deprivation linked to cognitive impairment
MDedge Hematology and Oncology
Symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment
MDedge Hematology and Oncology
Significant response to lacosamide in a patient with severe chemotherapy-induced peripheral neuropathy
MDedge Hematology and Oncology
ASCO: Upfront chemo prolongs life in men with advanced, hormone-naive prostate cancer
MDedge Hematology and Oncology
AUA: Very low-risk prostate cancers cause few deaths over 15 years
MDedge Hematology and Oncology